Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courtney D DiNardo

Showing results (1-10 of 434) with videos related to

Pageof 44
Sort By:
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
Hypomethylating agents and venetoclax in acute myeloid leukemiaCourtney D DiNardo
Best Practice & Research. Clinical Haematology|November 30, 2019
Which novel agents hold the greatest promise in AML?Courtney D DiNardo
Clinical Advances in Hematology & Oncology : H&O|January 30, 2014
Isolated myeloid sarcoma of the genitourinary systemCourtney D DiNardo
The New England Journal of Medicine|September 20, 2018
Ivosidenib in IDH1-Mutated Acute Myeloid LeukemiaCourtney D DiNardo
American Journal of Hematology|December 16, 2023
Toward an improved understanding of hypomethylating agent and venetoclax therapiesCourtney D DiNardo
Haematologica|May 4, 2026
Mutational profiling in acute myeloid leukemiaCourtney D DiNardo
Blood|September 5, 2015
Getting a handle on hereditary CEBPA mutationsCourtney D DiNardo
Blood Cancer Journal|August 16, 2025
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithmsNaseema Gangat, Courtney D Dinardo
Leukemia & Lymphoma|June 4, 2015
Time to revise the revised-International Prognostic Scoring System?Courtney D DiNardo, Farhad Ravandi
Future Oncology (London, England)|January 16, 2016
Great expectations in acute myeloid leukemiaMaliha Khan, Courtney D DiNardo
Pageof 44

Showing results (1-10 of 434) with videos related to

Sort By:
Pageof 44
Clinical Advances in Hematology & Oncology : H&O|February 17, 2021
Hypomethylating agents and venetoclax in acute myeloid leukemiaCourtney D DiNardo
Best Practice & Research. Clinical Haematology|November 30, 2019
Which novel agents hold the greatest promise in AML?Courtney D DiNardo
Clinical Advances in Hematology & Oncology : H&O|January 30, 2014
Isolated myeloid sarcoma of the genitourinary systemCourtney D DiNardo
The New England Journal of Medicine|September 20, 2018
Ivosidenib in IDH1-Mutated Acute Myeloid LeukemiaCourtney D DiNardo
American Journal of Hematology|December 16, 2023
Toward an improved understanding of hypomethylating agent and venetoclax therapiesCourtney D DiNardo
Haematologica|May 4, 2026
Mutational profiling in acute myeloid leukemiaCourtney D DiNardo
Blood|September 5, 2015
Getting a handle on hereditary CEBPA mutationsCourtney D DiNardo
Blood Cancer Journal|August 16, 2025
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithmsNaseema Gangat, Courtney D Dinardo
Leukemia & Lymphoma|June 4, 2015
Time to revise the revised-International Prognostic Scoring System?Courtney D DiNardo, Farhad Ravandi
Future Oncology (London, England)|January 16, 2016
Great expectations in acute myeloid leukemiaMaliha Khan, Courtney D DiNardo
Pageof 44